stockrow
Saturday 7 November 2026
Export GNPX’s income statement to Excel — free account
GENPREX
GNPX Healthcare Biotechnology
- EPS
- +95.0%
- Free cash flow
- −33.0%
Quarter to June 2026, against a year earlier
2.12
0.02
+0.95%
Follow GNPX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (4) | (3) | (12) | (11) | (18) | (21) | (24) | (31) | (21) | (16) | (16) | +16.4% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (4) | (3) | (12) | (11) | (18) | (21) | (24) | (31) | (21) | (16) | (16) | +16.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (16,780.83) | (12,680.22) | (39,560.44) | (29,251.29) | (22,417.58) | (18,461.54) | (21,978.02) | (24,819.29) | (5,871.58) | (382.42) | (172.88) | (34.3%) | ||||||
| Cash flow | (5,069.44) | (8,308.85) | (22,821.67) | (18,994.37) | (17,418.87) | (12,986.27) | (16,019.55) | (19,895.77) | (4,920.17) | (360.26) | (32.90) | (25.5%) | ||||||
| Capex | (363.87) | (242.58) | (344.33) | (398.35) | (160.00) | (65.82) | (54.27) | (57.26) | 212.67 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (5,433.32) | (8,551.42) | (23,166.00) | (19,392.72) | (17,578.87) | (13,052.09) | (16,073.82) | (19,953.03) | (4,707.50) | (360.26) | (32.90) | (26.0%) | ||||||
| Book value | 6,598.85 | 1,639.88 | 29,603.67 | 8,300.62 | 38,645.63 | 37,524.55 | 20,249.73 | 5,964.57 | 444.78 | 187.34 | 31.28 | (32.7%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +77.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (1) | (2) | (7) | (7) | (14) | (14) | (18) | (25) | (18) | (15) | (16) | +32.1% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | — | 1 | n/m | ||||||
| Free cash flow | (1) | (2) | (7) | (7) | (14) | (14) | (18) | (25) | (17) | (15) | (16) | +31.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 1 | (1) | 8 | 2 | 27 | 38 | 19 | 4 | 0 | 6 | 14 | +18.4% | |||||
| Net debt | (2) | 0 | (9) | (2) | (27) | (39) | (21) | (7) | (2) | (8) | (15) | +19.3% | ||||||
| Shareholders’ equity | 2 | 0 | 9 | 3 | 31 | 41 | 22 | 7 | 2 | 8 | 15 | +19.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (260.71) | (209.10) | (235.02) | (166.44) | (102.82) | (55.68) | (69.88) | (172.62) | (289.13) | (227.24) | (157.40) | +33.5 pt | |||||
| ROIC | (11,427.54) | (774.48) | (2,757.74) | (653.94) | (312.11) | (487.85) | (1,127.83) | (2,859.54) | (71,534.46) | (7,402.48) | 0.00 | +4,025.1 pt | ||||||
| ROE | (402.45) | (322.79) | (265.79) | (179.00) | (105.73) | (57.25) | (74.71) | (207.88) | (473.37) | (338.74) | (203.86) | +63.7 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 5 | 7 | 8 | 12 | 17 | 28 | 26 | 15 | 13 | — | +12.7% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
GENPREX vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| EDVA Splash Beverage Group, Inc. | $1.9M | — (loss-making) | — (loss-making) | −99.57% (below 0%: shrinking) | n/m | −95.72% (below 0%: shrinking) | 42.86% | 0.00% | Compare |
| GNPX GENPREX | $1.7M | — (loss-making) | — | — | n/m | −32.98% (below 0%: shrinking) | 0.00% | 0.00% | |
| PPCB Propanc Biopharma Inc | $1.7M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | Compare |
| XRTX XORTX Therapeutics Inc. | $1.7M | — (loss-making) | — | — | n/m | −318.40% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GOVX GeoVax Labs Inc. | $1.6M | — (loss-making) | — (loss-making) | +183.44% (above 0%: growing) | n/m | +15.81% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ITRMF Iterum Therapeutics PLC | $1.6M | — (loss-making) | — (loss-making) | +110.81% (above 0%: growing) | n/m | −179.15% (below 0%: shrinking) | 94.87% | (1,982.31%) | Compare |
| OGEN Oragenics, Inc. | $1.6M | — (loss-making) | — (loss-making) | −75.33% (below 0%: shrinking) | n/m | −66.37% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| VRAX Virax Biolabs Group Limited | $1.6M | — (loss-making) | — (loss-making) | — | −855.56% (below 0%: shrinking) | +32.24% (above 0%: growing) | (53.57%) | 0.00% | Compare |
| KAPA Kairos Pharma, Ltd. | $1.5M | — (loss-making) | — | — | n/m | −25.71% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $1.6M | — | — | +17.74% | — | −81.04% | 68.87% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
less than 1%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement